A Single-Dose, Open-Label, Parallel-Group Study to Assess the Pharmacokinetics of Inclisiran in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function (ORION-7)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 17 Sep 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Oct 2019 Results assessing safety and pharmacodynamics of inclisiran in patients with renal impairment from two studies (ORION-1 and ORION-7), published in the Mayo Clinic Proceedings.
27 May 2019 According to The Medicines Company media release, results of combined analysis of data (n=279) from ORION-1 and ORION-7 studies, presented at the 87th European Atherosclerosis Society (EAS) Congress 2019.
27 May 2019 Results of combined analysis (n=279) of data from ORION-1 and ORION-7 studies, presented in The Medicines Company media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com